Skip to main content
Top
Literature
1.
go back to reference Daviet F, Guervilly C, Baldesi O, Bernard-Guervilly F, Pilarczyk E, Genin A et al (2020) Heparin-Induced Thrombocytopenia in Severe COVID-19. Circulation 142:1875–1877CrossRefPubMedPubMedCentral Daviet F, Guervilly C, Baldesi O, Bernard-Guervilly F, Pilarczyk E, Genin A et al (2020) Heparin-Induced Thrombocytopenia in Severe COVID-19. Circulation 142:1875–1877CrossRefPubMedPubMedCentral
2.
go back to reference Nazy I, Jevtic SD, Moore JC, Huynh A, Smith JW, Kelton JG et al (2021) Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost 19:1342–1347CrossRefPubMed Nazy I, Jevtic SD, Moore JC, Huynh A, Smith JW, Kelton JG et al (2021) Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost 19:1342–1347CrossRefPubMed
3.
go back to reference Kotwal J, Chaudhary S, Manoj MG, Hasnain S, Nair V, Luthra M (2014) Heparin: Induced thrombocytopenia: Incidence and laboratory approach to diagnosis in Indians. Indian J Pathol Microbiol 57:31–38CrossRefPubMed Kotwal J, Chaudhary S, Manoj MG, Hasnain S, Nair V, Luthra M (2014) Heparin: Induced thrombocytopenia: Incidence and laboratory approach to diagnosis in Indians. Indian J Pathol Microbiol 57:31–38CrossRefPubMed
4.
go back to reference Adam Cuker GM, Arepally, Beng H, Chong DB, Cines A, Greinacher Y, Gruel et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2:3360–3392CrossRefPubMedPubMedCentral Adam Cuker GM, Arepally, Beng H, Chong DB, Cines A, Greinacher Y, Gruel et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2:3360–3392CrossRefPubMedPubMedCentral
5.
go back to reference Lingamaneni P, Gonakoti S, Moturi K, Vohra I, Zia M (2020) Heparin-Induced Thrombocytopenia in COVID-19. J Investig Med High Impact Case Rep 8:2324709620944091PubMedPubMedCentral Lingamaneni P, Gonakoti S, Moturi K, Vohra I, Zia M (2020) Heparin-Induced Thrombocytopenia in COVID-19. J Investig Med High Impact Case Rep 8:2324709620944091PubMedPubMedCentral
6.
go back to reference Parzy G, Daviet F, Persico N, Rambaud R, Scemama U, Adda M et al (2020) Prevalence and risk factors for thrombotic complications following venovenous extracorporeal membrane oxygenation: a CT scan study. Crit Care Med 48:192–199CrossRefPubMed Parzy G, Daviet F, Persico N, Rambaud R, Scemama U, Adda M et al (2020) Prevalence and risk factors for thrombotic complications following venovenous extracorporeal membrane oxygenation: a CT scan study. Crit Care Med 48:192–199CrossRefPubMed
Metadata
Title
Heparin Induced Thrombocytopenia in COVID-19 patients- a Diagnostic Dilemma
Authors
Surbhi Singh
Jyoti Kotwal
Publication date
26-10-2022
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2023
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-022-01593-3

Other articles of this Issue 2/2023

Indian Journal of Hematology and Blood Transfusion 2/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine